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Behc¸et’s disease is a multisystem inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis,
and skin lesions. The cause of Behc¸et’s disease remains unknown, but epidemiologic findings suggest that an autoimmune
process is triggered by an environmental agent in a genetically predisposed individual. An infectious agent could operate through
molecular mimicry, and subsequently the disease could be perpetuated by an abnormal immune response to an autoantigen in
the absence of ongoing infection. Potentia bacterial are Saccharomyces cerevisiae, mycobacteria, Borrelia burgdorferi, Helicobacter
pylori, Escherichia coli, Staphylococcus aureus, and Mycoplasma fermentans, but the most commonly investigated microorganism is
Streptococcus sanguinis. The relationship between streptococcal infections and Behc¸et’s disease is suggested by clinical observations
that an unhygienic oral condition is frequently noted in the oral cavity of Behc¸et’s disease patients. Several viral agents, including
herpes simplex virus-1, hepatitis C virus, parvovirus B19, cytomegalovirus, Epstein-Barr virus and varicella zoster virus, may also
have some role.
1. Introduction
Behc¸et’s disease is a multisystem inflammatory disorder
characterized by recurrent oral aphthous ulcers, genital
ulcers, uveitis, and skin lesions and generally presents with
remissions and exacerbations. It can frequently involve the
joints, gastrointestinal tract, and central nervous system
[1, 2].
2. Epidemiology
Behc¸et’s disease is most prevalent along the “Silk Road,” an
ancient trading route between the Mediterranean and East
Asia, where it is a major cause of morbidity. In Turkey,
the country with the highest incidence of the disease, the
prevalence is estimated to be between 110 and 420 per
100.000, whereas that in Japan is 13–20 per 100.000, and
the prevalence in the UK and USA is estimated at 1-2 per
100.000. The typical age of onset is in the third or fourth
decade of life and the male-to-female ratio varies with ethnic
origin [1, 3, 4].
The study of migrant populations led to interesting
epidemiological findings. Individuals from endemic areas
who have immigrated to areas with low prevalence of the
disease have an intermediate risk for developing the disease,
which points that environment has some role in Behc¸et’s
disease. Turkish individuals who have emigrated to Germany
have a significantly lower risk of disease than individuals of
Turkish origin living in Turkey, although their risk remains
higher than that of the native German population. Similarly,
the disease is virtually unknown in Japanese immigrants to
Hawaii, mainland USA, or South America despite a high
prevalence in Japan [5, 6].
3. Pathogenesis
The cause of Behc¸et’s disease remains unknown, but
epidemiologic findings suggest that an autoimmune process
is triggered by an infectious or environmental agent (possibly
local to a geographic region) in a genetically predisposed
individual [7, 8]. Whatever the stimulus is, the target
tissue seems to be the small blood vessels, with various
consequences of either vasculitis and/or thrombosis in many
organ systems [9].
The genetic susceptibility is strongly associated with the
presence of the HLA-B51 allele, with a stronger association in
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Turkish and Japanese patients in comparison to Caucasians.
The unusual geographic distribution of Behc¸et’s disease and
its close association with HLA-B51 may be the strongest
indicator that certain genes are directly responsible for
Behc¸et’s disease or of indirectly promoting the characteris-
tics of the underlying inflammatory changes. Other genes
located outside the HLA region have been also proposed,
including genes of coagulation factor V, intercellular adhe-
sion molecule-1 (ICAM-1), and endothelial nitric oxide
synthetase [10–12].
As is the case of other autoimmune diseases, there is
interest in an infectious etiology. Although there is no
information supporting the role of a single microorganism
as the specific cause, a problem with dysregulation in
innate immunity, with an altered response to more than
one infectious agent, is a generally accepted theory. An
infectious agent could operate through molecular mimicry.
This mimicked interaction or false signalling could attract
the inflammatory cells into the field of action, and this may
in turn result in vasculitis. Subsequently, the disease could
be perpetuated by an abnormal immune response to an
autoantigen in the absence of ongoing infection [13].
A viral cause was first postulated by Behc¸et in 1937
[14]. Evidence of ongoing infection with a variety of viral
agents has been sought. However, often there is only a history
of previous infection and/or seropositivity [2]. Although
herpetiform ulcers are unusual, herpes simplex virus-1
(HSV-1) is currently the most common virus associated with
Behc¸et’s disease. HSV DNA and serum antibodies against the
virus have been found in a higher proportion of patients with
Behc¸et’s disease than in controls, and circulating immune
complexes with the HSV-1 antigen have been reported.
HSV DNA has been demonstrated in the genital and
intestinal ulcers, but not in oral ulcers. However, anti-HSV
immunity is also common in normal subjects, and results
about therapeutic effects of antiviral treatment in Behc¸et’s
disease are scarce and controversial [15, 16]. Several other
viral agents, including hepatitis C virus, parvovirus B19,
cytomegalovirus, Epstein-Barr virus, and varicella zoster
virus, may also have some role [17–21].
Potential bacteria are a variety of streptococcal antigens,
Saccharomyces cerevisiae, mycobacteria, Borrelia burgdorferi,
Helicobacter pylori, Escherichia coli, Staphylococcus aureus,
Mycoplasma fermentans [22–27]. The infectious model is
also supported by observations that oral ulcers precede the
establishment of disease by months or years and disease
relapses are frequent. Thus, oral microbial flora have long
been implicated in the pathogenesis. The most commonly
investigated microorganism is Streptococcus. The relation-
ship between streptococcal infections and Behc¸et’s disease
is suggested by clinical observations that an unhygienic
oral condition including periodontitis, decayed teeth, and
chronic tonsillitis is frequently noted in the oral cavity
of Bechet’s disease patients [28]. It is not clear that the
predisposition of the patients is correlated with streptococcal
infection, but the uncommon oral Streptococcus sanguinis
serotypes (called KTH-1) and antibodies against the bacteria
are significantly increased in the oral flora and serum,
respectively, of patients with the disease compared with
healthy controls [29]. The patients show strong delayed-type
cutaneous hypersensitivity reactions against streptococcal
antigens in skin tests and sometimes Behc¸et’s disease symp-
toms were provoked by skin injection of the antigens [30].
The new criteria included hypersensitivity skin reactions
against streptococci in the diagnosis as one of the references
and the levels of disease severity of Behc¸et’s disease patients
[31]. S. sanguinis antigens share a sequence of amino acids
with one of the protein classes of the cellular membranes
called heat shock proteins (HSPs), which are expressed
above the cellular membrane in response to physiological
shocks and microbial stimulus [12]. Thus, HSPs are possible
candidate antigen for Behc¸et’s disease. Particularly, the
peptides of 65 kDa (HSP-65) derived from the bacteria show
considerable homology with those of the human 60 kDa
(HSP-60). Moreover, mycobacterial and human HSPs have
over 50% in sequence homology [32]. Studies have shown
that S. sanguis and HSP 60/65 kDa activate γδT cells in
Behc¸et’s disease patients but not controls. It is suggested
that, following the bacterial stimulus, mucous cells express
HSPs which are antigenic and reactive antimucous T cells
in susceptible individuals (molecular mimicry model) [30].
As for the most other autoimmune disorders, the Th1-type
polarization is predominant in Behc¸et’s disease [7]. γδT
lymphocytes have a role in the immune response to infec-
tions and in autoimmunity by recognizing bacteria-derived
and autologous antigens. Patients with Behc¸et’s disease have
increased numbers of activated γδT cells (in circulation and
in mucosal lesions), which produce inflammatory cytokines,
including IFN-γ, TNF-α, and IL-8. Culture of γδT lympho-
cytes from Behc¸et’s disease patients proliferates in response
to mycobacterial HSP-derived peptides and in response
to products from microorganisms in oral ulcers [11, 33].
Complex interactions between T cells, antigen presenting
cells, (APCs) and neutrophils are involved in the immune
pathogenesis of Behc¸et’s disease. Neutrophils are hyperactive
in Behc¸et’s disease, with increased chemotaxis, phagocytosis,
superoxide production and myeloperoxidase expression and
produce several cytokines [34]. Behc¸et’s disease lesionsmight
be induced with vascular reaction or lymphocytic vasculitis
as the immunological reaction by the APCs expressing the S.
sanguinis antigens [30]. Moreover, the amino acid sequence
of the peptides of Bes-1, a gene derived from oral S. sanguinis,
shows more than 60% similarity to the human intraocular
ganglion peptide, Brn-3b. These results suggest that Bes-1
might be an inducer for the retinal and neural involvement
possible in Behc¸et’s disease patients [35].
Pustular skin lesions are often not sterile andmay contain
Staphylococcus aureus and Prevotella species. Whether these
pustules are secondarily infected or whether the infections
play a pathogenic role in the development of pustular lesions
remains to be determined [36].
Anti-S. cerevisiae antibodies (ASCAs) may be especially
common in intestinal Bec¸het’s disease and are also increased
in healthy relatives of patients, according to the study by Choi
et al. who evaluated whether ASCA expression is associated
with clinical findings at diagnosis and the clinical course
of intestinal Behc¸et’s disease and found that the ASCA-
positive rate was 44.3% in intestinal Behc¸et’s disease but was
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not related to clinical findings at diagnosis and cumulative
relapse rates [37].
Mycoplasmas are known to exhibit molecular mimicry to
eukaryotic structures that may modulate immune responses
[27, 38].
4. Therapeutic Implications
Antiseptic agents and antibiotics are used to control micro-
bial contamination and secondary infection [39]. Chlorhexi-
dine gel and triclosan have been shown to reduce the number,
pain severity, and duration of aphthous ulcers [40, 41].
Antibiotics, especially tetracycline, has been widely used
in oral ulcers of Behc¸et’s disease for years. Tetracycline
mouthwash decreases pain severity and duration of oral
ulcers. Minocycline mouthwashes as compared to topical
tetracycline rinses resulted in significantly improved pain
control, by reducing the severity and duration of pain [42].
Minocycline reduces not only the growth of oral streptococci,
but also suppresses interleukins production fromT cells [43].
The effect of penicillin onmucocutaneous lesions and arthri-
tis has been examined in two different studies, and it was
found that prophylactic penicillin treatment reduced both
the mucocutaneous lesions and the arthritis episodes. Other
studies also showed that combination therapy, 1200000
units of benzathine-penicillin injected monthly plus 1mg
of oral colchicine daily for 4 months, was effective to
suppress Behc¸et’s disease symptoms, compared to colchicine
monotherapy [44–46].
Acyclovir is not effective in the treatment of oral and
genital ulceration [47].
5. Conclusion
The role of microorganisms in the pathogenesis of Behc¸et’s
disease has long been investigated, and there are ample
data on several microorganisms. However, none of these
infectious agents have been proved to cause Behc¸et’s disease.
Thus, a complex immune response might be generated to a
group of microorganisms that share common antigens rather
than to an infection due to a specific single microorganism.
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